Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience
Mutations in the <i>KRAS</i> gene are among the most common mutations observed in cancer cells, but they have only recently become an achievable goal for targeted therapies. Two <i>KRAS</i> inhibitors, sotorasib and adagrasib, have recently been approved for the treatment of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/2/325 |